Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections

(2013) Jodi Lestner et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacodynamics of Itraconazole against Aspergillus fumigatus in anIn VitroModel of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration

(2012) Zaid Al-Nakeeb et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Therapeutic Drug Monitoring of Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Patients Who Develop Gastrointestinal Graft-versus-Host Disease

(2012) J. Tonini et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant Aspergillus fumigatus in anIn VitroModel of Invasive Pulmonary Aspergillosis

(2012) Adam R. Jeans et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration

(2012) Michael J. Dolton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension

(2012) Gopal Krishna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity

(2012) Dimitra Mitsani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring

(2012) Michael J. Dolton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial

(2012) Wan Beom Park et al.   CLINICAL INFECTIOUS DISEASES

Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics–Based Analysis of Adult Patients With Invasive Fungal Infections

(2012) Andres Pascual et al.   CLINICAL INFECTIOUS DISEASES

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

(2012) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole

(2012) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies

(2012) Martin Hoenigl et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers

(2012) G. Krishna et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis

(2012) Yukihiro Hamada et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients

(2012) Alicia Gómez-López et al.   MEDICAL MYCOLOGY

Voriconazole-associated severe hyponatremia

(2012) Kye-Hyung Kim et al.   MEDICAL MYCOLOGY

Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience

(2012) Zdenek Racil et al.   MYCOSES

Reflections About Off-label Use of Anticancer Drugs

(2012) Alfredo Tartarone et al.   THERAPEUTIC DRUG MONITORING

Posaconazole Serum Level on Day 2 Predicts Steady State Posaconazole Serum Level

(2012) Myke R Green et al.   THERAPEUTIC DRUG MONITORING

Population Pharmacokinetics of Voriconazole in Adults

(2011) William W. Hope   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Concentration of Antifungal Agents within Host Cell Membranes: a New Paradigm Governing the Efficacy of Prophylaxis

(2011) P. Campoli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Children and Healthy Adults

(2011) Timothy A. Driscoll et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Adolescents and Healthy Adults

(2011) Timothy A. Driscoll et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

(2011) Peter F. Troke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation

(2011) David I. Marks et al.   BRITISH JOURNAL OF HAEMATOLOGY

Triazole Antifungal Agents in Invasive Fungal Infections

(2011) Cornelia Lass-Flörl   DRUGS

Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake

(2011) C. Eiden et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis

(2011) Alexander M. Bryant et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study

(2011) P. Soler-Palacin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Posaconazole: The Case for Therapeutic Drug Monitoring

(2011) Susan J Howard et al.   THERAPEUTIC DRUG MONITORING

Ultra-Performance Liquid Chromatography Mass Spectrometry and Sensitive Bioassay Methods for Quantification of Posaconazole Plasma Concentrations after Oral Dosing

(2010) B. Rochat et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Quantitation of Azoles and Echinocandins in Compartments of Peripheral Blood by Liquid Chromatography-Tandem Mass Spectrometry

(2010) F. Farowski et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Posaconazole Serum Concentrations among Cardiothoracic Transplant Recipients: Factors Impacting Trough Levels and Correlation with Clinical Response to Therapy

(2010) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

(2010) J. R. Wingard et al.   BLOOD

Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma

(2010) S H Jang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Correlation of in vitro activity and in vivo efficacy of itraconazole intravenous and oral solubilized formulations by testing Candida strains with various itraconazole susceptibilities in a murine invasive infection

(2010) K. Uchida et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tremor: a newly described adverse event with long-term itraconazole therapy

(2010) J. M Lestner et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy Volunteers

(2009) G. Krishna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin

(2009) W. W. J. van de Sande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene

(2009) E. Mavridou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults

(2009) D. Lebeaux et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

(2009) Roger J. M. Brüggemann et al.   CLINICAL INFECTIOUS DISEASES

Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring

(2009) Jodi M. Lestner et al.   CLINICAL INFECTIOUS DISEASES

Voriconazole Pharmacokinetics and Pharmacodynamics in Children

(2009) Michael Neely et al.   CLINICAL INFECTIOUS DISEASES

Combination Flucytosine and High‐Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in Malawi

(2009) Jesse C. Nussbaum et al.   CLINICAL INFECTIOUS DISEASES

Voriconazole concentrations and outcome of invasive fungal infections

(2009) S. Miyakis et al.   CLINICAL MICROBIOLOGY AND INFECTION

Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes

(2009) Kazuaki Matsumoto et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

(2009) Koki Ueda et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis

(2009) Zekaver Odabasi et al.   MYCOSES

International Interlaboratory Proficiency Testing Program for Measurement of Azole Antifungal Plasma Concentrations

(2008) R. J. M. Bruggemann et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers

(2008) G. Krishna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

(2008) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies

(2008) M. O. Karlsson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Hallucinations during Voriconazole Therapy

(2008) Dimitrios I. Zonios et al.   CLINICAL INFECTIOUS DISEASES

Therapeutic drug monitoring for triazoles

(2008) William W Hope et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Retrospective Serological Tests for Determining the Optimal Blood Concentration of Voriconazole for Treating Fungal Infection

(2008) Toshikatsu OKUDA et al.   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

(2007) A. Pascual et al.   CLINICAL INFECTIOUS DISEASES